Dr. Mandana Khalili is an Associate Professor of Medicine at the University of California, San Francisco (UCSF). Her long-term career objectives are to mentor early clinical investigators committed to patient-oriented research and to become a leader in efforts to improve our understanding of the pathogenesis of glucose intolerance in viral hepatitis. Her objectives during this award are to expand her research and mentoring program in multidisciplinary clinical and translational research in viral hepatitis, thereby increasing the pool of new investigators who ultimately become successful independent investigators. Dr. Khalili is an established investigator with significant mentoring experience who is committed to patient- oriented research, as evidenced by her ability to conduct high-quality research and her research leadership roles. Her multidisciplinary clinical and translational research program supported by ongoing extramural funding will serve as the platform for providing mentorship for junior investigators. She will capitalize on the rich academic environment of UCSF and its clinical research training resources, including K30 and K12 career development programs and the Clinical and Translational Sciences Institute to train her mentees to enable them to compete successfully for mentored career development awards in patient-oriented research and their transition to independence as clinical investigators. The pathophysiology, treatment, and prevention of both hepatitis C infection - the most common cause of liver disease in United States - and diabetes have been identified by the National Institutes of Health as high- priority areas of health research. Dr. Khalili's research goals are t continue to conduct clinical investigation in viral hepatitis and its complications that will provie insight into the relationship between hepatitis C and insulin action as well as host and viral interactions in disease pathogenesis. This research plan will provide mentoring and research training opportunities for new and junior clinical investigators in predictive modeling, in complex disease interactions, and in performing state-of-the-art physiologic measurements of insulin resistance and insulin secretion. In addition, the resources from her ongoing research activities will support mentees in performing patient-oriented research in viral hepatitis. The protected time afforded by this award will allow her to maintain her productivity and to achieve her mentorship and research goals.

Public Health Relevance

This award will provide support in mentoring early stage investigators in performing patient-oriented multidisciplinary research in viral hepatitis and glucose metabolism. Hepatitis C is the most common cause of liver disease and liver transplantation in United States and is frequently associated with diabetes. The studies outlined in this proposal will further elucidate the interplay between hepatitis C, host and environmental factors in pathogenesis of diabetes, a condition with high public health burden.

National Institute of Health (NIH)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Midcareer Investigator Award in Patient-Oriented Research (K24)
Project #
Application #
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Wang, Joe
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California San Francisco
Internal Medicine/Medicine
Schools of Medicine
San Francisco
United States
Zip Code
Wen, Jason W; Kohn, Michael A; Wong, Robert et al. (2018) Hospitalizations for Autoimmune Hepatitis Disproportionately Affect Black and Latino Americans. Am J Gastroenterol 113:243-253
Uribe, Lindsay A; Bacchetti, Peter; Gelman, Nicholas et al. (2018) Impact of Moderate Alcohol Discontinuation on Insulin Action and Secretion in Latinos With and Without Hepatitis C. Alcohol Clin Exp Res 42:492-499
Beck, Kendall R; Kim, Nicole J; Khalili, Mandana (2018) Direct Acting Antivirals Improve HCV Treatment Initiation and Adherence Among Underserved African Americans. Ann Hepatol 17:413-418
Khalili, Mandana; Wong, Robert J (2018) Underserved Does Not Mean Undeserved: Unfurling the HCV Care in the Safety Net. Dig Dis Sci 63:3250-3252
MĂ©ndez-Lagares, Gema; Lu, Ding; Chen, Connie et al. (2018) Memory T Cell Proliferation before Hepatitis C Virus Therapy Predicts Antiviral Immune Responses and Treatment Success. J Immunol 200:1124-1132
Lee, Briton; Holt, Edward W; Wong, Robert J et al. (2018) Race/ethnicity is an independent risk factor for autoimmune hepatitis among the San Francisco underserved. Autoimmunity 51:258-264
Kim, Nicole J; Locke, Cameron J; Park, Helen et al. (2018) Race and Hepatitis C Care Continuum in an Underserved Birth Cohort. J Gen Intern Med :
Kim, Nicole J; Magee, Catherine; Cummings, Cassie et al. (2018) Liver Disease Monitoring Practices After Hepatitis C Cure in the Underserved Population. Hepatol Commun 2:1274-1283
Mukhtar, Nizar A; Kathpalia, Priya; Hilton, Joan F et al. (2017) Provider, Patient, and Practice Factors Shape Hepatitis B Prevention and Management by Primary Care Providers. J Clin Gastroenterol 51:626-631
Beck, Kendall R; Kim, Nicole; Khalili, Mandana (2016) Sofosbuvir-Containing Regimens for Chronic Hepatitis C Are Successful in the Safety-Net Population: A Real-World Experience. Dig Dis Sci 61:3602-3608

Showing the most recent 10 out of 20 publications